We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Aveanna (AVAH) Q2 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Aveanna Healthcare (AVAH - Free Report) to post quarterly earnings of $0.17 per share in its upcoming report, which indicates a year-over-year decline of 5.6%. Revenues are expected to be $647.08 million, up 9.8% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Aveanna metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenue- PDS' will reach $530.01 million. The estimate indicates a change of +9.1% from the prior-year quarter.
Analysts expect 'Revenue- MS' to come in at $46.23 million. The estimate indicates a change of +6.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- HHH' will likely reach $65.79 million. The estimate suggests a change of +9.5% year over year.
Analysts forecast 'Hours - PDS' to reach 12099 hours. The estimate is in contrast to the year-ago figure of 11053 hours.
The average prediction of analysts places 'Revenue rate - MS' at $488.94 . Compared to the present estimate, the company reported $477.24 in the same quarter last year.
It is projected by analysts that the 'Unique patients served (UPS) - MS' will reach 95 . The estimate is in contrast to the year-ago figure of 91 .
According to the collective judgment of analysts, 'Revenue rate - PDS' should come in at $43.81 . Compared to the current estimate, the company reported $43.97 in the same quarter of the previous year.
Over the past month, Aveanna shares have recorded returns of -2.2% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #2 (Buy), AVAH will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Gear Up for Aveanna (AVAH) Q2 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect Aveanna Healthcare (AVAH - Free Report) to post quarterly earnings of $0.17 per share in its upcoming report, which indicates a year-over-year decline of 5.6%. Revenues are expected to be $647.08 million, up 9.8% from the year-ago quarter.
Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Aveanna metrics that are commonly tracked and forecasted by Wall Street analysts.
Analysts predict that the 'Revenue- PDS' will reach $530.01 million. The estimate indicates a change of +9.1% from the prior-year quarter.
Analysts expect 'Revenue- MS' to come in at $46.23 million. The estimate indicates a change of +6.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Revenue- HHH' will likely reach $65.79 million. The estimate suggests a change of +9.5% year over year.
Analysts forecast 'Hours - PDS' to reach 12099 hours. The estimate is in contrast to the year-ago figure of 11053 hours.
The average prediction of analysts places 'Revenue rate - MS' at $488.94 . Compared to the present estimate, the company reported $477.24 in the same quarter last year.
It is projected by analysts that the 'Unique patients served (UPS) - MS' will reach 95 . The estimate is in contrast to the year-ago figure of 91 .
According to the collective judgment of analysts, 'Revenue rate - PDS' should come in at $43.81 . Compared to the current estimate, the company reported $43.97 in the same quarter of the previous year.
View all Key Company Metrics for Aveanna here>>>Over the past month, Aveanna shares have recorded returns of -2.2% versus the Zacks S&P 500 composite's +3.4% change. Based on its Zacks Rank #2 (Buy), AVAH will likely outperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .